AAM Hits Out At ‘Flawed’ Medicare Price Negotiation List

Responding to the announcement by the US Centers for Medicare & Medicaid Services of the 15 additional drugs that will soon be subject to price negotiation – including Ozempic, Rybelsus and Wegovy – the Association for Accessible Medicines has called out the “short-sighted government price setting scheme” for undermining generic and biosimilar competition.

Price negotiation is creating barriers to competition and slowing down generic and biosimilar rivals (Shutterstock)

After 15 further drugs were announced as being opened up to price negotiation by the US Centers for Medicare & Medicaid Services, the response from the Association for Accessible Medicines to the US Department of Health and Human Services was clear and unambiguous: the Inflation Reduction Act’s price negotiation scheme doesn’t work.

More from Drug Pricing

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By 

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By 

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

 
• By 

Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”

More from Generics Bulletin

Richter Confirms European Tocilizumab Filing

Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.

Accord’s Denosumab Biosimilars Get Thumbs-Up From EMA

 
• By 

Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.

IGBA Warns Of Harmful Impact Of Tariffs On Generic Drug Supply

 
• By 

Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.